Special Target Pipeline

• 1.- IGF-1R antagonists
  
  

Special Company Pipelines

• 1.- DeCode Genetics (Iceland)
• 2.- Opsona Therapeutics (Ireland)
• 3.- Affimed Therapeutics (Germany)
• 4.- Prana Biotechnology (Australia)
• 5.- D-Pharm (Israel)
• 6.- Antisense Therapeutics (Australia)
  

• Insulin-like growth factor-1 receptor (IGF-1R) considered as hot target;
• At least six fully human or humanized antibodies in early clinical development or close to phase
• Antibodies internalize and downregulate the IGF-1R;
• Selective small molecule inhibitors more difficult to find;
• Other substance classes not relevant.
  

1.- DeCode Genetics (Iceland)

• Gene and target discovery based on population genetics
• Advanced clinical phase projects by using in-licensed “old drugs” against “new targets”;
• Three clinical stage projects and two IND candidates for 2006;
• Ongoing collaboration with Roche on PDE4 inhibitors for vascular diseases

2.- Opsona Therapeutics (Ireland)

• Core competence in toll-like receptors (TLR) and regulatory T-cells
• Spin-off from Trinity College, Dublin in 2003;
• Collaboration with Wyeth on TLR-targeted drug discovery and on new targets of the TLR pathway;
• Potential phase I start in 2006 of OPN-101 (immunomodulatory filamentous hemaglutinin A)

• Focus on bispecific, tetravalent recombinant antibodies without Fc part (Tandab);
• Bispecificity includes retargeting of NK cells or CTLs;
• Lead projects targeting CD19 and CD30 in cancer
  

4.- Prana Biotechnology (Australia)

• Focus on metal-protein attenuating compounds (MPACs);
• Clinical proof-of-concept shown in Alzheimer’s disease;
• Next generation copper/zink binder PBT2 in late phase I;
• Iron-binder NG2 with potential for Parkinson’s disease

• Membrane-activated chelator DP-b99 in phase II for stroke;
• Lipid-conjugate technology for regulated activation of prodrug;
• Valproic acid prodrug with fewer side effects in phase II for epilepsy;
• NSAID-lipid conjugate as Alzheimer’s disease candidate
  
  

• Antisense technology based on agreement with Isis Therapeutics;
• VLA4-antisense phase II project for multiple scleroris restarted;
• Topical antisense against IGF-1R in psoriasis needs dose optimization